Glenmark Gets USFDA Nod for Generic Blood Pressure Medicine
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil tablets, used in the treatment of high blood pressure.
The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company said in a statement.
These are generic equivalent of Benicar Tablets of Daiichi Sankyo, Inc.
Glenmark’s Olmesartan Medoxomil tablets will be manufactured by the company’s manufacturing facility located in Goa, it added.
Citing IMS Health sales data for the 12-month period ended March 2017, the company said Benicar achieved annual sales of about $950 million.
Glenmark’s current portfolio consists of 115 products authorised for distribution in the US market and approximately 69 ANDA’s (Abbreviated New Drug Application) pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 2.17 per cent up at Rs. 625.20 on BSE
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$169/UNIT FOB
2026-10-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Treat Acidity: Use medicines with this Pepto Bismol Active Ingredient
-
The battle for Medicine King! With the onslaught of K drug and the setback of Xiomele, the biggest variable in the world's TOP10 drug rankings in 2022 is who?
-
Facing Omicron, Where is the Next 'Special Medicine'?
-
What Are the Medicine that Requires Refrigeration? All You Need Know
-
China to focus on building quality and efficient TCM service system in next five years
-
Overwhelming influx of alliance procurement: orthopaedics and IOLs
-
Analysis of domestic veterinary drug raw materials market in the 42nd week of 2021 Part 2
-
How far is Chinese patent medicine from the ground?
-
Chinese medicine enters the era of plant extraction
-
Analysis of Import and Export of Chinese Medicines in 2019
Recommend Reading
-
![EU Set to Seek Import Quotas on PET, Epoxy Resins and Fibreglass as Trade Curbs Reach Chemicals]()
EU Set to Seek Import Quotas on PET, Epoxy Resins and Fibreglass as Trade Curbs Reach Chemicals
-
![Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports]()
Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports
-
![Refrigerant Prices Peak! Domestic Quotas Tighten, U.S. and U.K. Policies Add Fuel to the Fire]()
Refrigerant Prices Peak! Domestic Quotas Tighten, U.S. and U.K. Policies Add Fuel to the Fire
-
![Pesticide Market in Limbo: Prices Plunge Amid Weak Demand and Overcapacity—Only a Few Hold Firm]()
Pesticide Market in Limbo: Prices Plunge Amid Weak Demand and Overcapacity—Only a Few Hold Firm
-
![FDA Pushes New Approach to “No Artificial Colors” Claims]()
FDA Pushes New Approach to “No Artificial Colors” Claims
-
![This Week's Caustic Soda Prices Steady (8.10-8.14)]()
This Week's Caustic Soda Prices Steady (8.10-8.14)
-
![Ample Supply Leads to Continuous Decline in Dichloromethane Prices in China]()
Ample Supply Leads to Continuous Decline in Dichloromethane Prices in China
-
![This Week's Pure Benzene Market Prices Fluctuated and Increased in China (8.10-8.14)]()
This Week's Pure Benzene Market Prices Fluctuated and Increased in China (8.10-8.14)
-
![This week, the Aniline market in China continued to rise (8.10-8.14)]()
This week, the Aniline market in China continued to rise (8.10-8.14)
-
![Polyethylene Supply-Side Pressure Remains Unabated, Short-Term Market Maintains Weakness]()
Polyethylene Supply-Side Pressure Remains Unabated, Short-Term Market Maintains Weakness
